Navigation Links
Cell Therapeutics, Inc. Announces Reverse Stock Split
Date:8/25/2008

reatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements about the potential benefits of the reverse stock split that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the possibility that our stock price may decline following the reverse split, the possibility that we may not be able to sustain a trading price adequate to maintain the listing standards for the NASDAQ Global Market even with the split, the possibility that we may not meet other criteria for continued listing on the NASDAQ Global Market in the future even if our stock price stays above the minimum bid price, as well as the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: media@ctiseattle.com

http://www.celltherapeutics.com/media.htm

Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

http://www.celltherapeutics.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
2. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
3. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
7. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
8. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
9. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
10. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
11. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... MOUNTAIN VIEW, Calif., Feb. 25 Alexza,Pharmaceuticals, ... that it has initiated,its first Phase 3 ... an inhalation product candidate being developed for ... schizophrenia or bipolar disorder. Alexza,believes the novel, ...
... data by Dr. J.,Barthelow Classen shows that vaccines ... a strong family history of insulin dependent,diabetes. Previous ... recipients at a rate which exceeds their benefit ... particularly toxic to those,with a strong family history ...
... falling on only 9 percent of Californias Mojave ... electricity needs if the energy could be efficiently ... cell technologies are too expensive and inefficient for ... University researchers has developed a new anode coating ...
Cached Biology Technology:Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Special coating greatly improves solar cell performance 2
(Date:4/24/2014)... droplet of clear liquid can bend light, acting as ... have developed a new process to create inexpensive high ... apiece. , Because they,re so inexpensive, the lenses ... tools to detect diseases in the field, scientific research ... education in classrooms. , "What I,m really excited ...
(Date:4/23/2014)... to early fetal death according to a new study ... Hospital Los Angeles and Ulaanbaatar, Mongolia the coldest ... published today in the journal BMC Pregnancy and ... seasonal ambient air pollutants and pregnancy loss in Ulaanbaatar ... highest levels of air pollution of all world capitals, ...
(Date:4/23/2014)... release is available in French and ... Montreal, 23 April 2014Today, the CEC released its Conservation ... Collaborative Approach to Conservation, which identifies 29 priority conservation ... that includes 11 different protected areas in the states ... highly diverse arid and semi-arid habitats inhabited by rare ...
Breaking Biology News(10 mins):Bake your own droplet lens 2Bake your own droplet lens 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... Spanish . , Geraniums may hold the key ... 300 plant species and costs the ornamental plant industry $450 ... Agricultural Research Service (ARS). The beetle, Popillia ... plants, including ornamentals, soybean, maize, fruits and vegetables. But within ...
... book, "Strategic Bargaining and Cooperation in Greenhouse Gas Mitigations," ... work together to reduce carbon dioxide emissions. He also ... fuels whether they contribute to climate change or ... and I,m not making a scientific judgment here ...
... the expense of costly treatments for cancer and ... by growing these human therapeutic proteins in algaerapidly ... attention for their ability to produce biofuels. ... this week in Plant Biotechnology Journal, which sought ...
Cached Biology News:Geraniums could help control devastating Japanese beetle 2Cool model for a hot planet 2Cool model for a hot planet 3Study shows potential for using algae to produce human therapeutic proteins 2Study shows potential for using algae to produce human therapeutic proteins 3Study shows potential for using algae to produce human therapeutic proteins 4
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
... to LYZL6 ( Abpromise for ... Antigen: Synthetic peptide: DWLCL AFVE ... corresponding to amino acids 46-100 of ... Gene ID: 57151 ...
Request Info...
Biology Products: